Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort

Purpose

The purpose of the protocol is to assess the longitudinal attainment of person-centered and function related goals of patients who receive AbobotulinumtoxinA (aboBoNT-A) injections for adult lower limb spasticity over a period of 16 months.

Condition

  • Adult Lower Limb Spasticity

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Adult male and female subjects ≥18 years of age - Primary diagnosis with unilateral adult lower limb nonprogressive spasticity. - Subject able to take more than five steps with or without assistance. - Decision to treat the lower limb with aboBoNT-A by the care provider made prior to, and independently from, the decision to enroll the subject in the observational study as per country label. - Previously untreated with BoNT-A (i.e. naïve to BoNT-A), or previously treated with a BoNT-A (i.e. non-naïve to BoNT-A). For those who were previously treated with BoNTA, they should have responded to BoNT-A treatment and at least 12 weeks should have elapsed from prior injection. - Signed informed consent prior to participation in the study.

Exclusion Criteria

  • Prior history of nonresponsiveness to BoNT-A therapy - Previous treatment with BoNT-A of less than 12 weeks prior to enrolment in study. - Current participation in any other clinical study or have participated within the 12 weeks prior to the Inclusion visit (Visit 1) of this study. - Severe limitations in passive range of motion/contractures in the affected limb (MAS=4 in at least one of the joints in the lower limb). - Limb surgery or intrathecal baclofen therapy placement for spasticity within 3 months. - Nonambulatory subject. - Pregnant and lactating women. - Progressive neurological conditions or diagnosis of cerebral palsy.

Study Design

Phase
Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

More Details

Status
Completed
Sponsor
Ipsen

Study Contact